{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-141462","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.953082+00:00","generated_at":"2026-06-15T04:16:01.420648+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"UroGen Pharma Q1 2023 JELMYTO revenue $17.2M (+27% YoY); net loss $30.2M","bullets":["JELMYTO net product revenue $17.2M, up ~27% from $13.6M in Q1 2022.","Net loss $30.2M ($1.30 per share) vs $28.4M ($1.25 per share) in Q1 2022.","Cash and marketable securities $75.2M as of March 31, 2023.","Reiterated FY 2023 JELMYTO revenue guidance $76-86M; operating expenses $135-145M.","Topline data from ENVISION and ATLAS trials for UGN-102 expected summer 2023; NDA submission planned for 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-141462","json":"https://secwatch.observer/filing/0001193125-23-141462.json","markdown":"https://secwatch.observer/filing/0001193125-23-141462.md","text":"https://secwatch.observer/filing/0001193125-23-141462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/0001193125-23-141462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/d365198d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:16:01.420648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7390bda4f2fcc973bfc08f4edaf5d892a0f983d7","claim":"UroGen Pharma Ltd. reported the first quarter ended March 31, 2023 results: revenue $17.2 million, net income $30.2 million. Guidance reaffirmed.","evidence_excerpt":"99.1 UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments • Reported JELMYTO ® Q1 2023 net product revenues of $17.2 million, an increase of ~27% from Q1 2022 • Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023 PRINCETON, N.J. May 11,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/0001193125-23-141462-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$17.2 million"},{"label":"Net income","value":"$30.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}